title: Cancer: drug-tolerant insurgents.
authors.forename: Paul
authors.initials: P
authors.lastname: Workman
authors.forename: Jon
authors.initials: J
authors.lastname: Travers
mesh_terms: D005075:Biological Evolution; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use; D002999:Clone Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D019008:Drug Resistance, Neoplasm / Q000235:genetics / Q000502:physiology*; D004361:Drug Tolerance / Q000235:genetics / Q000502:physiology; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008954:Models, Biological; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D056485:Retinoblastoma-Binding Protein 2 / Q000235:genetics / Q000378:metabolism; D012641:Selection, Genetic
chemical_list: D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C070050:KDM5A protein, human; D056485:Retinoblastoma-Binding Protein 2; D002945:Cisplatin